Translational diabetes research
Anders Rosengren, MD PhD, is heading the Translational Diabetes Research group at Lund University Diabetes Centre and is also working as a physician at the Endocrinology Clinic at Skåne University Hospital. His research integrates clinical investigations, bioinformatics and experimental studies and aims to better understand the pathophysiology of type 2 diabetes and to identify more specific treatment targeted at the underlying disease mechanisms.
He is PI for the "Detailed Mapping of Type 2 Diabetes" (DIACT) study, which is a longitudinal patient study that investigates how the major pathophysiological components in type 2 diabetes are interlinked and develop over time. This is combined with global genetic, gene expression and metabolite data to identify biomarkers associated with pathophysiological components.
Network analysis and other bioinformatics approaches are used to integrate genetic and gene expression data from the patients and to identify disease genes. Candidate genes identified from these analyses are studied experimentally to investigate underlying disease mechanisms. Moreover, a method for drug repositioning is used that compares the gene networks that are perturbed in T2D with a large library of gene expression signatures from drugs to identify potential anti-diabetic compounds.
Anders Rosengren has extensive international collaborations, which includes e.g. Sage Bionetworks in Seattle and University of Oxford. Anders Rosengren was appointed a Ragnar Söderberg researcher in Medicine 2013. He has also recently been awarded a 5-year Future Research Leader grant by the Swedish Foundation for Strategic Research.
Anders Rosengren is also PI for PriusHealth, a study aiming to develop new research-based web tool for patients with type 2 diabetes. This tool will integrate biological and lifestyle aspects of type 2 diabetes and aims to improve patient self-management. The tool is developed in close collaboration with patients in a research study.
Patients with type 2 diabetes who are interested in participating in the PriusHealth study to develop and test this new treatment tool may contact us via www.forskningsstudie.se.
Grants as PI
Ragnar Söderberg Foundation - Ragnar Söderberg Researcher in Medicine 2013
Swedish Foundation for Strategic Research - Future Research Leader 2013
NovoNordisk Foundation - Excellence grant
Swedish Research Council
European Foundation for the Study of Diabetes (EFSD)
ALF Region Skåne
Royal Physiographic Society
Albert Påhlsson Foundation
Rising Star Award 2013, the European Foundation for the Study of Diabetes
Medeon Prize for Innovations in Diabetes Research 2011
Scandinavian Society for the Study of Diabetes, Young Investigator Award 2010
Tang Y, Axelsson A, Spegel P, Andersson LE, Mulder H, Groop L, Renström E, Rosengren AH
Genotype-based treatment of type 2 diabetes with an alpha2A-adrenergic receptor antagonist
Science Translational Medicine Oct 2014.
Mahdi T, Hänzelmann S, Salehi A, Muhammed SJ, Reinbothe TM, Tang Y, Axelsson AS, Zhou Y, Jing X, Almgren P, Krus U, Taneera J, Blom AM, Lyssenko V, Esguerra JLS, Hansson O, Eliasson L, Derry J, Zhang E, Wollheim CB, Groop L, Renström E, Rosengren AH.
Secreted Frizzled-Related Protein 4 Reduces Insulin Secretion and Is Overexpressed in Type 2 Diabetes.
Cell Metabolism 3;16:625-33. 2012.
Rosengren AH, Braun M, Mahdi T, Andersson SA, Travers ME, Shigeto M, Zhang E, Almgren P, Ladenvall C, Axelsson AS, Edlund A, Gram Pedersen M, Jonsson A, Ramracheya R, Tang Y, Walker JN, Barrett A, Johnson PRV, Lyssenko V, McCarthy MI, Groop L, Salehi A, Gloyn AL, Renström E, Rorsman P and Eliasson L.
Reduced insulin exocytosis in human pancreatic beta-cells with gene variants linked to type-2 diabetes.
Diabetes 61(7):1726-33. 2012.
Rosengren AH, Jokubka R, Tojjar D, Granhall C, Hansson O, Li DQ, Nagaraj V, Reinbothe TM, Tuncel J, Eliasson L, Rorsman P, Salehi A, Groop L, Lyssenko V, Luthman H, Renström E.
Overexpression of alpha2A-adrenergic receptors contributes to type 2-diabetes.
Science 327:217. 2010